Glaukos stock steadies premarket after a 13% surge — what GKOS investors watch next
Glaukos shares slipped 0.1% to $120.90 in premarket trading Thursday after surging 13.5% the previous session. The company reported record Q4 sales of $143.1 million, up 36%, and reaffirmed 2026 revenue guidance. Analysts raised price targets, citing momentum in iDose TR and the upcoming Epioxa launch. Glaukos ended 2025 with $282.6 million in cash and no debt.